Abstract: A method for treating a patient having a disease associated with undesirable or uncontrolled cell proliferation such as cancer and restenosis is provided. The method comprises: delivering to the patient a therapeutically effective amount of 9-nitro-20(S)-camptothecin in combination with an effective amount of an antibiotic agent such as doxorubicin.

Abstract: A pharmaceutical formulation is provided for delivering paclitaxel in vivo comprising: water and micelles comprising paclitaxel and a pharmaceutically-acceptable, water-miscible solubilizer forming the micelles, the solubilizer selected from the group consisting of solubilizers having the general structuresR.sub.1 COOR.sub.2, R.sub.1 CONR.sub.2, and R.sub.1 COR.sub.2,wherein R.sub.1 is a hydrophobic C.sub.3 -C.sub.50 alkane, alkene or alkyne and R.sub.2 is a hydrophilic moiety. The solubilizer is selected such that it does not have a pKa less than about 6.

Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.

Abstract: Disclosed are compositions comprising paclitaxel; and a pharmaceutically-acceptable, water-miscible, non-aqueous solvent, together with kits comprising the composition and methods of using the composition.

Abstract: The invention provides a method for the solubilization and/or stabilization of polypeptides, especially proteins, using cyclodextrin selected from the group consisting of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin. Solubilized and/or stabilized compositions comprising a polypeptide, especially a protein, and the selected cyclodextrin are also described.

Abstract: Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.

Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anticancer drugs and anti-ulceration effective or anti-irritatioin effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.

Abstract: The invention provides a method for the solubilization and/or stabilization of polypeptides, especially proteins, using a cyclodextrin selected from the group consisting of hydroxypropyl, hydroxyethyl, glucosyl, maltosyl and maltotriosyl derivatives of .beta.- and .gamma.-cyclodextrin. Solubilized and/or stabilized compositions comprising a polypeptide, especially a protein, and the selected cyclodextrin are also described.

Abstract: Compositions of matter comprising a substituted cyclodextrin and cytotoxic compound, especially cytotoxic drugs such as antibiotic, anti-fungal and anti-neoplastic, drugs are claimed. The compositions cause significantly less ulceration compared to the same formulation of cytotoxic compound without cyclodextrin compound when extravasated. The compositions may also cause less vascular irritation compared to the same formulation of cytotoxic compound without cyclodextrin when administered intravenously without extravasation. Compositions of matter comprising watersoluble cytotoxic agents, especially anti-cancer drugs and anti-ulceration effective or anti-irritation effective amounts of cyclodextrin compounds are also claimed. Methods for reducing the likelihood of ulceration and or irritation when administering the compositions according to the invention are also disclosed and claimed.

Abstract: Blend of olefin sulfonate detergent with other detergents such as sulfates of higher alcohol or alkylbenzenesulfonates.

Abstract: There are disclosed two new antibiotics, 6"-deoxykanamycin B and 6"-deoxytobramycin. These compounds are highly active, broad spectrum antibiotics.

Abstract: Blend of olefin sulfonate detergent with other detergents such as sulfates of higher alcohol or alkylbenzenesulfonates.

Abstract: Calcium .alpha.-p-chlorophenoxyisobutyrate, particularly as its novel monohydrate, when combined with about one to two parts by weight of calcium carbonate in oral dosage form for use in mammals, and especially man, provides a safe and effective composition for reducing elevated blood levels of cholesterol, triglycerides and/or low density lipoproteins and/or increasing fibrinolytic activity and/or decreasing platelet aggregation. A preferred embodiment is a capsule containing 500 mgm. calcium carbonate and 250 or 500 mgm. crystalline calcium .alpha.-p-chlorophenoxyisobutyrate monohydrate having the empirical formula C.sub.10 H.sub.10 ClO.sub.3 Ca.sub.1/2.H.sub.2 O.